Management of Inherited von Willebrand Disease in 2006

ABSTRACT

The aim of treatment of von Willebrand disease (VWD) is to correct the dual defect of hemostasis (i.e., the abnormal platelet adhesion due to reduced and/or dysfunctional von Willebrand factor [VWF] and the abnormal coagulation expressed by low levels of factor [F] VIII). Desmopressin acetate (DDAVP) is the treatment of choice for type 1 VWD because it can induce release of normal VWF from cellular compartments. Prospective studies on biological response versus clinical efficacy of DDAVP in VWD types 1 and 2 are in progress to explore its benefits and limits as a therapeutic option. In type 3 and in severe forms of type 1 and 2 VWD, DDAVP is not effective, and for these patients plasma virally inactivated concentrates containing VWF and FVIII are the mainstay of treatment. Several intermediate- and high-purity VWF/FVIII concentrates are available and have been shown to be effective in clinical practice (bleeding and surgery). New VWF products almost devoid of FVIII are now under evaluation in clinical practice. Although thrombotic events are rare in VWD patients receiving repeated infusions of concentrates, there is some concern that sustained high FVIII levels may increase risk of postoperative venous thromboembolism. Dosage and timing of VWF/FVIII administrations should be planned to keep the FVIII level between 50 and 150 IU/dL. Appropriate dosage and timing in repeated infusions are also very important in patients exposed to secondary long-term prophylaxis for recurrent bleedings.

KEYWORDS

von Willebrand disease - von Willebrand factor - desmopressin - factor VWF/VIII concentrates - efficacy and safety of concentrates - secondary long-term prophylaxis

REFERENCES

• 1 Castaman G, Federici A B, Rodeghiero F, Mannnucci P M. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.  Haematologica. 2003;  88 94-108
• 2 Federici A B, Castaman G, Mannucci P M. Guidelines for the diagnosis and management of VWD in Italy.  Haemophilia. 2002;  8 607-621
• 3 Mannucci P M. Treatment of von Willebrand disease.  N Engl J Med. 2004;  351 683-694
• 4 Mannucci P M, Ruggeri Z M, Pareti F I, Capitanio A. A new pharmacological approach to the management of hemophilia and von Willebrand disease.  Lancet. 1977;  1 869-872
• 5 Federici A B, Mazurier C, Berntorp E et al.. Biological response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.  Blood. 2004;  103 2032-2038
• 6 Revel-Vilk S, Schmugge M, Carcao M D et al.. Desmopressin (DDAVP) responsiveness in children with von Willebrand disease.  J Pediatr Hematol Oncol. 2003;  25 874-879
• 7 Federici A B. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.  Blood Coagul Fibrinolysis. 2005;  16(Suppl 1) S17-S21
• 8 Mannucci P M. Venous thromboembolism in von Willebrand disease.  Thromb Haemost. 2002;  88 378-379
• 9 Mannucci P M, Federici A B. Antibodies to von Willebrand factor in von Willebrand disease.  Adv Exp Med Biol. 1995;  386 87-92
• 10 Bergamaschini L, Mannucci P M, Federici A B et al.. Posttransfusion anaphylactic reaction in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor.  J Lab Clin Med. 1995;  125 348-355
• 11 Ciavarella N, Schiavoni M, Valenzano E et al.. Use of recombinant factor VIIa (Novoseven) in the treatment of two patients with type III von Willebrand disease and an inhibitor against von Willebrand factor.  Haemostasis. 1996;  26 150-154
• 12 Boyer-Neumann C, Dreyfus M, Wolf M et al.. Multi-therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease.  J Thromb Haemost. 2003;  1 190-192
• 13 Marchese M, De Cristofaro R, Federici A B et al.. Duodenal and gastric Dieulafoy's lesions in a patient with type 2A von Willebrand's disease.  Gastrointest Endosc. 2005;  61 322-325
• 14 Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease.  Blood Coagul Fibrinolysis. 2005;  16(suppl 1) S23-S26
• 15 Federici A B, Gianniello F, Canciani M T, Mannucci P M. Secondary long-term prophylaxis in severe patients with von Willebrand disease: an Italian cohort study.  Blood. 2005;  106 507a , (abst 1782)